专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20020127694A1 2786, a novel human aminopeptidase 审中-公开
公开(公告)号：US20020127694A1
公开(公告)日：2002-09-12
申请号：US10056253
申请日：2002-01-24
申请人： Millennium Pharmaceuticals, Inc.
发明人： Rosana Kapeller-Libermann , David White , Kyle J. MacBeth
IPC分类号： C12N009/64 , C07H021/04 , C12P021/02 , C12N005/06
CPC分类号： C12N9/48
摘要： The present invention relates to a newly identified human aminopeptidase. The invention also relates to polynucleotides encoding the aminopeptidase. The invention further relates to methods using the aminopeptidase polypeptides and polynucleotides as a target for diagnosis and treatment in aminopeptidase-related disorders. The invention further relates to drug-screening methods using the aminopeptidase polypeptides and polynucleotides to identify agonists and antagonists for diagnosis and treatment. The invention further encompasses agonists and antagonists based on the aminopeptidase polypeptides and polynucleotides. The invention further relates to procedures for producing the aminopeptidase polypeptides and polynucleotides.

2. 发明申请

US20030224417A1 14400, 2838, 14618, 15334, 14274, 32164, 39404, 38911, 26904, 31237, 18057, 16405, 32705, 23224, 27423, 32700, 32712 and 12216, novel seven-transmembrane proteins/G-protein coupled receptors 审中-公开
标题翻译： 14400,2838,14618,15334,14274,32164,39404,38911,26904,313237,18057,16405,32705,23224,27423,32700,32712和12216，新型七跨膜蛋白/ G蛋白偶联受体
公开(公告)号：US20030224417A1
公开(公告)日：2003-12-04
申请号：US10400991
申请日：2003-03-27
申请人： Millennium Pharmaceuticals, Inc.
发明人： Maria A. Glucksmann , Nadine S. Weich , John Joseph Hunter , David White , Kyle J. MacBeth , Mark J. Williamson , Rachel E. Meyers , Miyoung Chun
IPC分类号： C12Q001/68 , G01N033/53 , C07K014/705 , C12P021/02 , C12N005/06 , A61K038/17
CPC分类号： G01N33/566 , A01K2217/05 , A61K38/00 , C07K14/705 , C07K14/723 , C07K2319/00 , C12N9/16 , G01N2333/726
摘要： The present invention relates to a newly identified receptor belonging to the superfamily of G-protein-coupled receptors. The invention also relates to polynucleotides encoding the receptor. The invention further relates to methods using the receptor polypeptides and polynucleotides as a target for diagnosis and treatment in receptor-mediated disorders. The invention further relates to drug-screening methods using the receptor polypeptides and polynucleotides to identify agonists and antagonists for diagnosis and treatment. The invention further encompasses agonists and antagonists based on the receptor polypeptides and polynucleotides. The invention further relates to procedures for producing the receptor polypeptides and polynucleotides.
摘要翻译：本发明涉及属于G蛋白偶联受体的超家族的新鉴定的受体。本发明还涉及编码受体的多核苷酸。本发明还涉及使用受体多肽和多核苷酸作为在受体介导的病症中进行诊断和治疗的靶标的方法。本发明还涉及使用受体多肽和多核苷酸鉴定用于诊断和治疗的激动剂和拮抗剂的药物筛选方法。本发明还包括基于受体多肽和多核苷酸的激动剂和拮抗剂。本发明还涉及产生受体多肽和多核苷酸的方法。

3. 发明申请

US20020119517A1 Leptin induced genes 审中-公开
标题翻译：瘦素诱导基因
公开(公告)号：US20020119517A1
公开(公告)日：2002-08-29
申请号：US09804006
申请日：2001-03-12
申请人： Millennium Pharmaceuticals, Inc., Delaware corporation
发明人： David White , Jianghong Zhou , Louis A. Tartaglia
IPC分类号： C07K014/435 , C07H021/04 , C12P021/02 , C12N005/06
CPC分类号： C07K14/4722 , A61K38/00 , C07K14/47 , C07K2319/00 , C12N9/1051
摘要： Six genes whose expression is induced by leptin are disclosed (LIG46; LIG56; Tgtp, encoding a T cell-specific GTP-binding protein; LRG-47, encoding an interferon (IFN) inducible protein; RC10-II, encoding a subunit of a 20S brain proteasome; and Stra13, encoding a retinoic acid inducible protein). These six leptin-inducible genes and the proteins they encode represent targets for the development of therapeutic agents for use in modulating body weight. For example, agents that alter the expression or activity of one or more of the leptin-induced proteins can be used to modulate body weight. Such agents can be identified using cellular, in vitro, or in vivo assays which monitor the expression or activity of one or more of the six leptin-induced proteins. Potentially useful therapeutic agents can also be identified through the use of assays designed to identify agents that bind to one of the leptin-induced proteins. The leptin-induced genes of the invention and the proteins they encode may themselves be useful therapeutically and diagnostically.
摘要翻译：公开了表达由瘦蛋白诱导的六个基因（LIG46; LIG56; Tgtp，编码T细胞特异性GTP结合蛋白; LRG-47，编码干扰素（IFN）诱导蛋白; RC10-II，编码a 20S脑蛋白酶体;和Stra13，编码视黄酸诱导蛋白）。这六种瘦蛋白可诱导基因及其编码的蛋白质代表用于开发用于调节体重的治疗剂的靶标。例如，改变一种或多种瘦蛋白诱导蛋白质的表达或活性的试剂可用于调节体重。可以使用监测六种瘦素诱导的蛋白质中的一种或多种的表达或活性的细胞，体外或体内测定来鉴定此类试剂。潜在有用的治疗剂也可以通过使用设计用于鉴定结合瘦蛋白诱导蛋白之一的试剂的测定来鉴定。本发明的瘦蛋白诱导的基因及其编码的蛋白本身可以在治疗和诊断上有用。

4. 发明申请

US20040110204A1 Compositions, kits,and methods for prognostication, diagnosis, prevention, and treatment of bone-related disorders and other disorders 审中-公开
标题翻译：用于预后，诊断，预防和治疗骨相关疾病和其他疾病的组合物，试剂盒和方法
公开(公告)号：US20040110204A1
公开(公告)日：2004-06-10
申请号：US10666807
申请日：2003-09-18
申请人： Millennium Pharmaceuticals, Inc.
发明人： David White
IPC分类号： C12Q001/68
CPC分类号： C12Q1/6883 , C12Q2600/158
摘要： The invention relates to compositions, kits, and methods for predicting, detecting, inhibiting, and alleviating bone-related disorders and other disorders. Examples of bone-related disorders include osteoporosis, Paget's disease, hyperthyroidism, hyperparathyroidism, osteomalacia, chronic renal failure, Cushing's syndrome, osteogenic cancers, and non-osteogenic cancers that have metastasized to bone tissue.
摘要翻译：本发明涉及用于预测，检测，抑制和减轻骨相关疾病和其它病症的组合物，试剂盒和方法。骨相关疾病的例子包括已转移到骨组织的骨质疏松症，佩吉特氏病，甲状腺机能亢进，甲状旁腺功能亢进，骨软化症，慢性肾功能衰竭，库兴综合征，成骨癌和非成骨癌。

5. 发明申请

US20040067513A1 84569, a novel human map kinase family member and uses therefor 审中-公开
标题翻译： 84569，一种新的人类地图激酶家族成员，并用于此
公开(公告)号：US20040067513A1
公开(公告)日：2004-04-08
申请号：US10619780
申请日：2003-07-15
申请人： Millennium Pharmaceuticals, Inc.
发明人： David White , Olga Tayber
IPC分类号： C12Q001/68 , C07H021/04 , C12N009/12 , C07K016/40
CPC分类号： C12N9/1205
摘要： The present invention relates to methods and compositions for the diagnosis and treatment of metabolic disorders, including, but not limited to, obesity, diabetes, overweight anorexia, or cachexia. The invention provides isolated nucleic acids molecules, designated 84569 nucleic acid molecules, which encode a novel MAP kinase family member. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 84569 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which an 84569 gene has been introduced or disrupted. The invention still further provides isolated 84569 proteins, fusion proteins, antigenic peptides and anti-84569 antibodies. Methods of use of the provided 84569 compositions for screening, diagnostic and therapeutic methods in connection with metabolic disorders are also disclosed.
摘要翻译：本发明涉及用于诊断和治疗代谢紊乱的方法和组合物，包括但不限于肥胖症，糖尿病，超重厌食症或恶病质。本发明提供编码新型MAP激酶家族成员的分离的核酸分子，命名为84569核酸分子。本发明还提供反义核酸分子，含有84569个核酸分子的重组表达载体，其中引入了表达载体的宿主细胞，以及其中84569基因被引入或破坏的非人类转基因动物。本发明还进一步提供分离的84569蛋白，融合蛋白，抗原肽和抗-84569抗体。还公开了所提供的84569组合物用于与代谢紊乱有关的筛选，诊断和治疗方法的方法。

6. 发明申请

US20040006016A1 Novel 27875, 22025 ,27420, 17906, 16319, 55092 and 10218 molecules and uses therefor 有权
标题翻译：小分子27875,22025,27420,17906,16319,55092和10218分子及其用途
公开(公告)号：US20040006016A1
公开(公告)日：2004-01-08
申请号：US10386414
申请日：2003-03-11
申请人： Millennium Pharmaceuticals, Inc.
发明人： Rosana Kapeller-Libermann , David White , Keith E. Robison , Kyle J. MacBeth , Joseph M. Carroll , William James Cook , Rachel E. Meyers , Miyoung Chun , Mark J. Williamson
IPC分类号： A61K038/17 , C12Q001/68 , C07H021/04 , C12N009/00 , C12P021/02 , C12N005/06
CPC分类号： G01N33/5008 , A61K38/00 , C12N9/1007 , C12N9/16 , C12N9/6489 , C12Q1/37 , C12Q1/6883 , C12Q2600/158 , C12Y301/04017 , G01N33/5011 , G01N33/502 , G01N33/56983 , G01N33/56994 , G01N33/57426 , G01N33/5761 , G01N33/5767 , G01N33/68 , G01N2333/916 , G01N2333/96486 , G01N2500/04
摘要： The invention provides isolated nucleic acids molecules, designated 27875, 22025, 27420, 16319, 55092 and 10218 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 27875, 22025, 27420, 16319, 55092 and 10218 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 27875, 22025, 27420, 16319, 55092 and 10218 gene has been introduced or disrupted. The invention still further provides isolated 27875, 22025, 27420, 17906, 16319, 55092 or 10218 proteins, fusion proteins, antigenic peptides and anti-27875, 22025, 27420, 17906, 16319, 55092 or 10218 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
摘要翻译：本发明提供分离的核酸分子，命名为27875,22025,27420,16319,55092和10218核酸分子。本发明还提供反义核酸分子，含有27875,22025,27420,16319,55092和10218核酸分子的重组表达载体，已经引入表达载体的宿主细胞，以及非人类转基因动物，其中27875,22025， 27420,16319,55092和10218基因已被引入或破坏。本发明还进一步提供了分离的27875,22025,27420,17906,16319,55092或10218蛋白，融合蛋白，抗原肽和抗27875,22025,27420,17906,16319,55092或10218抗体。还提供了利用本发明组合物的诊断和治疗方法。

7. 发明申请

US20030232044A1 Use for endothelin converting enzyme 2 (ECE-2) in the diagnosis and treatment of metabolic disorders 审中-公开
标题翻译：用于内皮素转化酶2（ECE-2）在代谢紊乱的诊断和治疗中的应用
公开(公告)号：US20030232044A1
公开(公告)日：2003-12-18
申请号：US10453764
申请日：2003-06-03
申请人： Millennium Pharmaceuticals, Inc.
发明人： David White
IPC分类号： A61K038/48 , C12Q001/68 , G01N033/53 , C07K016/40
CPC分类号： C12Y304/24071 , A61K38/4886 , C12Q1/6883 , C12Q2600/158 , C12Y304/00 , G01N2333/96486
摘要： The invention relates to methods and compositions for the diagnosis and treatment of metabolic disorders including, but not limited to, obesity, diabetes, overweight, insulin resistance, anorexia, and cachexia; and disorders of appetite regulation, including hyperphagia. The invention further provides methods for identifying a compound capable of treating a metabolic disorder or a disorder of appetite regulation. The invention also provides methods for identifying a compound capable of modulating a metabolic activity or regulation of appetite. Yet further, the invention provides methods for modulating a metabolic activity and methods for modulating appetite regulation. In addition, the invention provides methods for treating a subject having a metabolic disorder or a disorder of appetite regulation characterized by aberrant ECE-2 polypeptide activity or aberrant ECE-2 nucleic acid expression.
摘要翻译：本发明涉及用于诊断和治疗代谢紊乱的方法和组合物，包括但不限于肥胖症，糖尿病，超重，胰岛素抵抗，厌食和恶病质; 和食欲调节障碍，包括食欲不振。本发明还提供了鉴定能够治疗代谢紊乱或食欲调节障碍的化合物的方法。本发明还提供了鉴定能调节代谢活性或调节食欲的化合物的方法。此外，本发明提供了调节代谢活性的方法和调节食欲调节的方法。此外，本发明提供了治疗以异常的ECE-2多肽活性或异常的ECE-2核酸表达为特征的代谢紊乱或食欲调节障碍的受试者的方法。

8. 发明申请

US20030165491A1 22196, a novel human aminopeptidase 审中-公开
标题翻译： 22196，一种新的人氨基肽酶
公开(公告)号：US20030165491A1
公开(公告)日：2003-09-04
申请号：US10192445
申请日：2002-07-10
申请人： Millennium Pharmaceuticals, Inc.
发明人： Rosana Kapeller-Libermann , David White , Inmaculada Silos-Santiago
IPC分类号： G01N033/567 , C07H021/04 , A61K038/48 , C12N009/64 , C12P021/02 , C12N005/06
CPC分类号： C12N9/48 , A01K2217/05 , A61K38/00 , Y02A50/411 , Y10S435/81 , Y10S435/975
摘要： The present invention relates to a newly identified human aminopeptidase. The invention also relates to polynucleotides encoding the aminopeptidase. The invention further relates to methods using the aminopeptidase polypeptides and polynucleotides as a target for diagnosis and treatment in aminopeptidase-related disorders. The invention further relates to drug-screening methods using the aminopeptidase polypeptides and polynucleotides to identify agonists and antagonists for diagnosis and treatment. The invention further encompasses agonists and antagonists based on the aminopeptidase polypeptides and polynucleotides. The invention further relates to procedures for producing the aminopeptidase polypeptides and polynucleotides.
摘要翻译：本发明涉及新鉴定的人类氨基肽酶。本发明还涉及编码氨基肽酶的多核苷酸。本发明还涉及使用氨基肽酶多肽和多核苷酸作为在氨基肽酶相关疾病中进行诊断和治疗的靶标的方法。本发明还涉及使用氨基肽酶多肽和多核苷酸鉴定用于诊断和治疗的激动剂和拮抗剂的药物筛选方法。本发明还包括基于氨基肽酶多肽和多核苷酸的激动剂和拮抗剂。本发明还涉及生产氨基肽酶多肽和多核苷酸的方法。

9. 发明申请

US20040231005A1 2786, a novel human aminopeptidase 失效
标题翻译： 2786，一种新型人氨基肽酶
公开(公告)号：US20040231005A1
公开(公告)日：2004-11-18
申请号：US10767308
申请日：2004-01-29
申请人： Millennium Pharmaceuticals, Inc.
发明人： Rosana Kapeller-Libermann , David White , Kyle J. MacBeth
IPC分类号： A01K067/00 , C07H021/04 , C12N009/64
CPC分类号： C12N9/48
摘要： The present invention relates to a newly identified human aminopeptidase. The invention also relates to polynucleotides encoding the aminopeptidase. The invention further relates to methods using the aminopeptidase polypeptides and polynucleotides as a target for diagnosis and treatment in aminopeptidase-related disorders. The invention further relates to drug-screening methods using the aminopeptidase polypeptides and polynucleotides to identify agonists and antagonists for diagnosis and treatment. The invention further encompasses agonists and antagonists based on the aminopeptidase polypeptides and polynucleotides. The invention further relates to procedures for producing the aminopeptidase polypeptides and polynucleotides.
摘要翻译：本发明涉及新鉴定的人类氨基肽酶。本发明还涉及编码氨基肽酶的多核苷酸。本发明还涉及使用氨基肽酶多肽和多核苷酸作为在氨基肽酶相关疾病中进行诊断和治疗的靶标的方法。本发明还涉及使用氨基肽酶多肽和多核苷酸鉴定用于诊断和治疗的激动剂和拮抗剂的药物筛选方法。本发明还包括基于氨基肽酶多肽和多核苷酸的激动剂和拮抗剂。本发明还涉及生产氨基肽酶多肽和多核苷酸的方法。

10. 发明申请

US20040176296A1 Novel ITALY, LOR-2, STRIFE, TRASH, BDSF, LRSG, and STMST protein and nucleic acid molecules and uses therefor 审中-公开
标题翻译：新型ITALY，LOR-2，STRIFE，TRASH，BDSF，LRSG和STMST蛋白和核酸分子及其用途
公开(公告)号：US20040176296A1
公开(公告)日：2004-09-09
申请号：US10806018
申请日：2004-03-22
申请人： Millennium Pharmaceuticals, Inc.
发明人： Douglas A. Holtzman , Sean A. McCarthy , Kyle J. MacBeth , Samantha J. Busfield , Yang Pan , David White , Mehran M. Khodadoust , Wei Gu
IPC分类号： A61K038/17 , C07H021/04 , C12N009/00
CPC分类号： C12N9/0022 , A01K2217/05 , A61K38/00 , C07K14/47 , C07K14/4702 , C07K14/525 , C07K14/705 , C07K14/70575 , C07K14/70578 , C07K14/723 , C07K2319/00 , Y02A50/411
摘要： Novel ITALY, LOR-2, STRIFE, TRASH, BDSF, LRSG, and STMST polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length ITALY, LOR-2, STRIFE, TRASH, BDSF, LRSG, and STMST proteins, the invention further provides isolated ITALY, LOR-2, STRIFE, TRASH, BDSF, LRSG, and STMST fusion proteins, antigenic peptides and anti-ITALY, LOR-2, STRIFE, TRASH, BDSF, LRSG, and STMST antibodies. The invention also provides ITALY, LOR-2, STRIFE, TRASH, BDSF, LRSG, and STMST nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which an ITALY, LOR-2, STRIFE, TRASH, BDSF, LRSG, and STMST gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.
摘要翻译：公开了新型意大利，LOR-2，STRIFE，TRASH，BDSF，LRSG和STMST多肽，蛋白质和核酸分子。除了分离的全长ITALY，LOR-2，STRIFE，TRASH，BDSF，LRSG和STMST蛋白之外，本发明还提供了分离的ITALY，LOR-2，STRIFE，TRASH，BDSF，LRSG和STMST融合蛋白，抗原肽和抗ITALY，LOR-2，STRIFE，TRASH，BDSF，LRSG和STMST抗体。本发明还提供意大利，LOR-2，STRIFE，TRASH，BDSF，LRSG和STMST核酸分子，含有本发明的核酸分子的重组表达载体，已经引入表达载体的非宿主细胞其中引入或破坏意大利，LOR-2，STRIFE，TRASH，BDSF，LRSG和STMST基因的转基因动物。还提供利用本发明组合物的诊断，筛选和治疗方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式